Medical education and research funding patterns play a central role in how we understand hormone health. Historically, medical school curricula have focused heavily on male physiology as the default baseline for human health. This creates a blind spot. When students spend more time studying male reproductive endocrinology than female hormonal fluctuations, they naturally develop a gendered view of testosterone.
Research funding follows these same established pathways. Most clinical trials investigating androgen deficiency focus on aging men and erectile dysfunction. Because money flows toward these specific outcomes, we lack robust data on how low testosterone affects women, such as impacts on bone density or cognitive function. This leaves clinicians without the tools needed to diagnose women accurately.
The result is a clinical environment where women reporting symptoms like fatigue or loss of libido often face dismissal. If the textbooks and the funded studies don't highlight female androgen deficiency, doctors are less likely to look for it. We aren't just dealing with a lack of awareness; we are dealing with a structural lack of evidence. Until funding and textbooks diversify, the medical field will continue to treat testosterone deficiency as a uniquely masculine concern, ignoring the biological reality of how these hormones function across all bodies.
